Follistatin 344 is the predominant circulating isoform of follistatin, a naturally occurring glycoprotein that binds and neutralizes myostatin (GDF-8), activin A, and other TGF-β family members. First identified in ovarian follicular fluid as an activin antagonist, it is recognized as a potent endogenous inhibitor of myostatin, making it a subject of interest in skeletal muscle cell research. According to pmc.ncbi.nlm.nih.gov, follistatin has been investigated in the context of myostatin inhibition in preclinical research models. This research-grade lyophilized protein is produced under strict quality controls and provided with full analytical documentation. For Research Use Only. Not for human use.
Key Scientific Attributes
High-purity Follistatin 344 (≥ 98% by HPLC/SDS-PAGE, recombinant human sequence)
Verified 344-amino-acid mature isoform (Gly30–Asp344) with correct disulfide bonding
Lyophilized formulation for maximum long-term stability
Full Certificate of Analysis (COA) with HPLC, SDS-PAGE, myostatin/activin binding ELISA, and endotoxin testing
Manufactured in GMP-aligned, ISO-compliant facilities
Suitable for myostatin blockade and TGF-β antagonism studies in laboratory settings
Research-Referenced Attributes (Based on scientific literature; not therapeutic claims.)
Studies suggest Follistatin 344 may modulate satellite cell activity and myostatin signalling pathways in in vitro and preclinical research models, as noted by openmedscience.com
Research indicates potential interactions with activin A signalling pathways relevant to cancer cachexia and reproductive biology research contexts
Investigated in laboratory models relevant to neuromuscular biology and TGF-β superfamily signalling.
Why Researchers Choose This Follistatin 344
Recombinant human sequence with documented myostatin-neutralizing activity in binding assays
Transparent analytical data (HPLC/SDS-PAGE + functional myostatin binding assay)
Suitable for muscle physiology, neuromuscular biology, and TGF-β signalling research laboratories
Competitive research pricing with bulk options